CARB-X, a global public-private partnership leading the fight against antibiotic resistance, is holding a historic event where it will announce its initial investment in companies engaged in the discovery and development of life-saving antibacterial products. This exciting portfolio contains the first innovative antibacterial products to earn the distinction of being Powered by CARB-X.

The event is co-hosted by CARB-X, the Infectious Diseases Society of America, and The Pew Charitable Trusts.

Powered by CARB-X Launch: Thursday March 30th 2017, 4:00-5:00pm GMT

The CARB-X Mission

Did you know?

Last year antibiotic resistant infections were associated with 23,000 deaths in the United States, 25,000 in Europe, and over 700,000 worldwide.

CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) was launched in July 2016 to accelerate pre-clinical product development in the area of antibiotic-resistant infections, one of the world’s greatest health threats. CARB-X was established by BARDA and NIAID of the U.S. Department of Health and Human Services, who committed $250 million in new funds over the next five years to increase the number of antibacterial products in the drug-development pipeline. It reflects a new approach to how antibacterial research and drug development is identified, funded and accelerated to the clinic. The CARB-X goal is to move promising antibacterial candidates through the critical early stages of product development so they can attract additional private or public investment for clinical stage development.

The creation of CARB-X was prioritized in the 2015 US National Action Plan on Combating Antibiotic-Resistant Bacteria (CARB), which called for a biopharmaceutical accelerator to spur pre-clinical product development.